Intervention

MK-2206

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions8

Lead sponsors shown4

Clinical trials

5 shown

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerNCT01248247 · 2011-06-02

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNCT01306045 · 2011-02-08

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)NCT01295632 · 2011-02-01

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerNCT01240941 · 2011-02-01

A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)NCT00963547 · 2009-09-15

Common conditions

Advanced Cancer1 Advanced Solid Tumors1 Breast Cancer1 Carcinoma, Non-Small-Cell Lung1 Carcinoma, Small Cell Lung1 Carcinoma, Thymic1 Lung Cancer1 Metastatic Breast Cancer1

Leading sponsors

Merck Sharp & Dohme LLC2 M.D. Anderson Cancer Center1 National Cancer Institute (NCI)1 Vanderbilt-Ingram Cancer Center1

Trial status mix

COMPLETED3

TERMINATED1

WITHDRAWN1

Phase mix

PHASE23

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.